KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $139,000.

  • Aquestive Therapeutics' Depreciation and Depletion fell 12.58% to $139,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $565,000, marking a year-over-year decrease of 36.16%. This contributed to the annual value of $640,000 for FY2024, which is 44.49% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Depreciation and Depletion stood at $139,000, which was down 0.71% from $140,000 recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Depreciation and Depletion peaked at $743,000 during Q1 2021, and registered a low of $139,000 during Q1 2025.
  • Over the past 3 years, Aquestive Therapeutics' median Depreciation and Depletion value was $165,000 (recorded in 2024), while the average stood at $200,364.
  • Per our database at Business Quant, Aquestive Therapeutics' Depreciation and Depletion increased by 14.24% in 2023 and then tumbled by 62.60% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Depreciation and Depletion (Quarterly) stood at $717,000 in 2021, then plummeted by 52.02% to $344,000 in 2022, then rose by 14.24% to $393,000 in 2023, then plummeted by 62.60% to $147,000 in 2024, then declined by 12.58% to $139,000 in 2025.
  • Its Depreciation and Depletion stands at $139,000 for Q3 2025, versus $140,000 for Q2 2025 and $139,000 for Q1 2025.